Breast Cancer | Oncology Today with Dr Neil Love: Key Presentations on Breast Cancer from the 2022 ASCO Annual Meeting

Featuring an interview with Dr Angela DeMichele, including the following topics:

• Staining for HER2 expression and clinical relevance of HER2-0 breast cancer (0:00)
• Biology of HER2-mutated breast cancer; sequencing of sacituzumab govitecan and trastuzumab deruxtecan for estrogen receptor (ER)-negative breast cancer (4:21)
• Role of trastuzumab deruxtecan in HER2-low, ER-positive breast cancer; biologic rationale for targeting HER3 with patritumab deruxtecan (11:39)
• Ongoing clinical trials of tucatinib for HER2-positive locally advanced or metastatic breast cancer: HER2CLIMB-04 and HER2CLIMB-05 (17:16)
• Recent data with and biomarkers of response for sacituzumab govitecan for triple-negative breast cancer (TNBC); benefits of chemotherapy for disease with a BRCA mutation (22:22)
• Molecular alterations associated with PARP inhibitor response and potential implications for clinical practice (25:45)
• Current role of PARP inhibitors, immunotherapy, chemotherapy, and combination therapies for TNBC (28:57)
• Potential role of sacituzumab govitecan for ER-positive, HER2-negative breast cancer (33:54)
• Tolerability of capivasertib; using genomic testing to identify tumor subtypes less responsive to endocrine therapy (37:24)
• Using genomic risk scores to inform treatment for ER-positive, HER2-negative breast cancer that has spread to lymph nodes (43:04)

CME information and select publications